<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We have identified ten patients with <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) and one patient with <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> with megakaryocytic crisis who displayed an inv(3)(q21q26) </plain></SENT>
<SENT sid="1" pm="."><plain>Seven of them had an additional <z:mp ids='MP_0004026'>monosomy</z:mp> 7 </plain></SENT>
<SENT sid="2" pm="."><plain>Most of them had a <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) preceding <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, <z:mpath ids='MPATH_458'>normal</z:mpath> or <z:hpo ids='HP_0001894'>increased platelet counts</z:hpo>, increased number of megakaryocyte, megakaryocytic <z:mpath ids='MPATH_589'>dysplasia</z:mpath>, and erythroid <z:mpath ids='MPATH_589'>dysplasia</z:mpath> </plain></SENT>
<SENT sid="3" pm="."><plain>There was a high incidence of resistance to induction chemotherapy, short remission time, and early relapse </plain></SENT>
<SENT sid="4" pm="."><plain>Seven patients were immunologically analyzed </plain></SENT>
<SENT sid="5" pm="."><plain>The main immunophenotypes were as follow: CD7+, CD34+, HLA-DR+, CD38+, CD13+, CD33+, CDw65+, CD2-, CD3-, CD4-, CD8-, CD19+, CD20-, CD11b- </plain></SENT>
<SENT sid="6" pm="."><plain>Our results suggest that the <z:hpo ids='HP_0001909'>leukemia</z:hpo> with inv(3)(q21q26) represents a new cytogenetic-clinicopathologic subtype, characterized by 1) abnormal megakaryopoiesis and multiple hematopoietic lineage involvement; 2) an antecedent <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>; 3) poor response to conventional chemotherapy; and 4) expression of CD7, CD34, CD38, HLA-DR, CD13, and CD33 antigens </plain></SENT>
<SENT sid="7" pm="."><plain>We propose that the <z:e sem="disease" ids="C1608408" disease_type="Neoplastic Process" abbrv="">malignant transformation</z:e> in patients with inv(3)(q21q26) occurs in an early stem cell prior to lineage commitment </plain></SENT>
</text></document>